Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-08

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To explore the predictive value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population;
2. To evaluate the prognostic value of ctDNA in HER2 positive breast cancer neoadjuvant therapy population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment

NCT06087120

Breast Cancer Female Stage II Breast Cancer Stage III Breast Cancer +2 more

RECRUITING

Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy

NCT05649475

Stage I-III Breast Cancer

UNKNOWN

Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients

NCT03881384

Breast Neoplasms

UNKNOWN

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

NCT05079074

Metastatic Breast Cancer Circulating Tumor DNA Gene Abnormality

COMPLETED

Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer

NCT03260192

Breast Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study plans to enroll 50 HER2 positive breast cancer patients in early stage (T2-3, N0-1, M0)/local late stage (T2-3, N2-3, M0 or T4a-c, Nany, M0), collect baseline tumor tissue samples of patients, as well as peripheral blood samples of multiple nodes at baseline, during new adjuvant therapy, after new adjuvant therapy (before surgery), and after surgery, detect the mutation of tumor tissue through 1021 panel, and conduct ctDNA detection of peripheral blood samples based on personalized panel design based on tumor tissue specific mutations, to explore the efficacy prediction and prognostic predictive value of ctDNA in HER2 positive new adjuvant therapy population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Neoadjuvant HER2-positive Breast Cancer Circulating Tumor DNA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ctDNA-MRD

This study is an observational non intervention study that only tests peripheral blood samples from different treatment nodes of the subjects, without interfering with the normal clinical diagnosis and treatment process of the patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women with breast cancer diagnosed clinically and pathologically, aged 18-75 years;
2. ECOG performance score is 0-1;
3. Histologically confirmed as early or locally advanced invasive breast cancer: the diameter of the primary tumor is more than 2 cm, and HER2 is positive (confirmed by IHC or FISH).
4. The patient did not receive any treatment for breast cancer before enrollment;
5. Having lesions measurable according to RECIST 1.1 standards;
6. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up; 7) Breast cancer patients who plan to use neoadjuvant therapy.

Exclusion Criteria

1. Patients with known metastatic or stage IV breast cancer;
2. There are other untreated malignant tumors other than breast cancer;
3. Patients with one or more serious systemic diseases that, in the eyes of researchers, can impair their ability to complete research;
4. According to the researchers' assessment, there may be other factors that could force the subjects to terminate the study midway, such as suffering from other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the subjects or the collection of experimental data.
5. Unable to follow up with the study according to the determined clinical follow-up period;
6. Cannot accept or provide specified efficacy evaluation methods such as CT.
7. Unable to obtain sufficient tumor tissue samples or peripheral blood samples.

\- 1) Patients with known metastatic or stage IV breast cancer; 2) There are other incurable malignant tumors present; 3) One or more serious systemic diseases that, in the eyes of researchers, can impair the patient's ability to complete the study; 4) According to the researcher's judgment, there are other factors that may cause the subject to be forced to terminate the study midway, such as other serious illnesses (including mental illness) requiring concurrent treatment, severe abnormal laboratory test values, family or social factors, which may affect the safety of the subject or the collection of trial data.

5\) Unable to follow the determined clinical follow-up period in conjunction with the study for follow-up; 6) Unable to accept or provide specified efficacy evaluation methods such as CT.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No